mazetx.com - MAZE Company profit before taxes, interest and amortization
Strategic alliances with major pharmaceutical companies help Maze Therapeutics Inc (MAZE) management reduce costs in the search for new drugs. Actual EBITDA reflects the impact of these processes, where the 0.00 mark serves as a key metric. Efficiency is further evidenced by the implementation of "green chemistry," strict control over laboratory waste disposal, and adherence to basic energy-saving standards in offices.
Maze Therapeutics, Inc. (MAZE) - metric breakdowns and financial figures
- stock quotes and analyst forecast:
- issuer market value details:
- issuer book value statistics:
- business debt structure and liquidity details:
All Debt to Shareholders' Equity Ratio Maze Therapeutics Inc|MAZE - Long-Term Debt to Capital|Short-Term Debt to Capital Maze Therapeutics Corp|MAZE - Company Debts|Debts to Book Capitalization Ratio Maze Therapeutics Inc|MAZE - Company Long-Term Debts|Short-Term Debt Maze Therapeutics|Quick Ratio mazetx.com
- earnings and market ratios statistics:
MAZE - Net Income|Future Net Profit Maze Therapeutics Inc|MAZE - P/E Multiple|Market Cap to Projected Earnings Maze Therapeutics|MAZE - PEG Multiple|Enterprise Value to EBITDA Ratio Maze Therapeutics, Inc.|MAZE - Profit before payment of interest, taxes and amortization|Net earnings per share for the last four quarters Maze Therapeutics|MAZE - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months mazetx.com|MAZE - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Maze Therapeutics Inc
- sales revenue and business income indicators:
Analysis of all company metrics:Maze Therapeutics Inc, MAZE
Maze Therapeutics Inc (MAZE) is scaling drug development through strategic outsourcing of clinical trials and manufacturing. This operational benefit trend reflects net cash flow from operating activities before depreciation and interest. Comparing current values to historical peaks allows for a distinction between business expansion and a cyclical downturn. The growth of this metric confirms the efficiency of external distribution, although it requires a comparison with the cost of capital. A steady recovery in profit justifies the fundamental strength of the market price.
Who Maze Therapeutics Inc competes with
Operating income before deduction of amortization Tempus AI Inc (TEM)|QGEN - Profit before payment of interest, taxes and amortization|Income before deduction of interest, taxes and amortization IONS (Ionis Pharmaceuticals, Inc.)|RGEN: Operating profit EBITDA|Avidity - Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization CRSP|Profit before interest, taxes and amortization genedx.com WGS|Operating profit before deduction of amortization RARE (Ultragenyx Corp)|BEAM (Beam Therapeutics) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA SRPT (Sarepta Therapeutics Inc)|Operating income before deduction of amortization Twist Bio (TWST)|TXG: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization NTLA (Intellia Therapeutics)|Stoke Therapeutics (STOK) - Profit before payment of interest, taxes and amortization|BioLife Corp (BLFS) - Operating profit EBITDA|WVE (wavelifesciences.com) - Operating profit EBITDA|Sionna Pharma - Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA PRME|TSHA (Taysha Gene Therapies) - Income before deduction of interest, taxes and amortization|Profit before payment of interest, taxes and amortization uniQure QURE|MGTX: Operating profit before amortization|REGENXBIO Inc - Operating profit EBITDA|Profit before interest, taxes and amortization Solid Corp|Ocugen (OCGN) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Pacific Biosciences|Operating profit before deduction of amortization BNTC|Operating profit before deduction of amortization Design Therapeutics Inc (DSGN)|Operating profit EBITDA RCKT|Operating profit EBITDA 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Operating profit before deduction of amortization|KRRO: Operating profit before amortization|Editas Corp - Operating profit EBITDA|SLN: Profit before payment of interest, taxes and amortization|PRQR (ProQR) - Operating profit before deduction of amortization|Operating profit before amortization CDXS|Profit before payment of interest, taxes and amortization sangamo.com|Operating profit before amortization NAUT (Nautilus Biotechnology)|Operating profit EBITDA MGX|Operating income before deduction of amortization Precision BioSciences Inc.|Operating profit EBITDA GBIO (Generation Bio Co)|Operating profit EBITDA Boundless Bio, Inc BOLD|Exicure Corp - Operating profit EBITDA|Operating income before deduction of amortization Imunon IMNN|PHIO: Operating profit EBITDA|MBIO: Company profit before taxes, interest and amortization|Profit before payment of interest, taxes and amortization TransCode Therapeutics, Inc.|Operating profit EBITDA Bionano Genomics, Inc.|Profit before payment of interest, taxes and amortization Applied DNA (APDN)|Profit before payment of interest, taxes and amortization BLUE (bluebird bio, Inc.)|Operating profit EBITDA IPA (immunoprecise.com)|Operating profit EBITDA Omega OMGA|OMIC - Profit before payment of interest, taxes and amortization|RGLS - Operating profit EBITDA|Syros Pharmaceuticals Inc. (SYRS) - Profit before payment of interest, taxes and amortization|TBIO (Telesis Bio, Inc.) - Profit before payment of interest, taxes and amortization|TCON (TRACON Pharmaceuticals Inc.) - Operating profit EBITDA|Profit before interest, taxes and amortization Unity Bio UBX
